Multiple myeloma is a cancer derived from malignant plasma cells. Conventional mono-targeting CAR T-cell therapies targeting BCMA have yielded remission in treated patients, however, a large proportion relapses due to BCMA antigen escape as a result of low antigen density. The development for effective CAR T-cell therapy with long-term remission is needed.
Learn from Prof. de Larrea how expressing two CARs on a single cell enhances the strength of CAR T-cell/target cell interactions, prevents BCMA escape-driven relapse, and how cell avidity measurements contributed to their findings in this webinar.
Key learning points:
- Dual-targeting CARs exhibit superior binding interactions to target cells expressing both antigens compared with mono-targeting CARs.
- Dual-targeting CARs display stronger intercellular binding strength in BCMA-deficient target cells expressing GPRC5D, validating the ability of dual-targeting approaches to overcome BCMA antigen escape.
- Cell avidity measurements with the z-Movi correlate with treatment outcomes in mouse models, suggesting that cell avidity measurements are reliable predictors of CAR T-cell efficacy
